The Future Management of IPF: Advanced
Diagnostic & Treatment Strategies

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session at the 2017 Fall Forum. If you participated in
the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from February 20, 2018 to February 28, 2019

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from
Boehringer Ingelheim

Idiopathic pulmonary fibrosis (IPF) is a devastating disease associated with irreversible destruction of the lung(s) which progressively worsens, making it difficult for patients to breathe as well as keep adequate levels of oxygen in the bloodstream. The condition frequency increases with age, is more common in men than in women, and has a median survival rate of 4 years or less from the time of diagnosis. IPF is the most common of the idiopathic interstitial pneumonias and typically has a poor prognosis as the disease exhibits a gradual onset, making it difficult to diagnosis early. Earlier diagnosis begins with elicitation of a thorough and extensive medical history that includes a review of symptoms/signs suggestive of a systemic disorder, occupational and environmental exposures, use of medications and drugs, and family medical history. Despite a growing prevalence, patients with IPF continue to suffer delays in diagnosis, increased costs, and a reduction in patient quality of life and overall survival.

Treatment strategies for IPF aim at managing the symptoms and slowing disease progression to best maintain a patient’s quality of life. The therapeutic landscape is rapidly evolving and current and emerging therapies are shown to slow disease progression which ultimately brings about a need for earlier diagnosis and intervention in IPF. More recently, therapeutic options for IPF have evolved to include targeted agents that have the ability to individualize treatment for patients. The standard of care for IPF includes oxygen supplementation, management of co-morbidities, lung transplants, and implementing nintedanib and pirfenidone, according to updated guidelines.

Upon Completion of this activity, participants will be able to:

  • Identify the available guidelines and approaches for the management of patients with IPF

  • Assess the diagnostic workup and criteria as well as the role of the multidisciplinary team in ensuring an early and accurate diagnosis of IPF

  • Explore the clinical data and emerging research related to IPF treatment

  • Discuss the current and emerging therapies that reflect current evidence and available guidelines that are individualized to patients

  • Evaluate the appropriate process with patients and/or caregivers in overcoming barriers in IPF management

Faculty: Charles Vega, MD, FAAFP
Health Sciences Clinical Professor
UC Irvine Department of Family Medicine
Associate Dean for Diversity and Inclusion
UC Irvine School of Medicine
Executive Director
UC Irvine Program in Medical Education for the Latino Community (PRIME-LC)


Dr. Vega has no relevant financial relationships to disclose. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jeremy Williams has no real or perceived financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by an educational grant from
Boehringer Ingelheim

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue